Vacinas contra a COVID-19 e os erros inatos da imunidade (ou imunodeficiências primárias)
COVID-19 vaccines and inborn errors of immunity (or primary immunodeficiencies)
Eli Mansur; Anete Sevciovic Grumach; Antonio Condino Neto; Helena Fleck Velasco; Carolina Sanchez Aranda; Gesmar Rodrigues Silva Segundo; Renan Augusto Pereira; Carolina Cardoso de Mello Prando; Pedro Giavina-Bianchi; Dewton de Moraes Vasconcelos; Ana Karolina Barreto Berselli Marinho; Lorena de Castro Diniz; Ekaterini Simões Goudouris
Resumo
Desde o início da pandemia de COVID-19 iniciou-se a corrida por uma imunização ativa, eficaz e segura. Todas as vacinas desenvolvidas até o momento vêm demostrando boa eficácia na prevenção de casos graves de COVID-19, de hospitalizações e mortes. Muitos pacientes com erros inatos da imunidade (EII) não terão capacidade de desenvolver uma resposta imune semelhante ao indivíduo imunocompetente. Esses pacientes foram incluídos nos grupos prioritários definidos pelo Ministério da Saúde, como pessoas entre 18 a 59 anos com uma ou mais das comorbidades, incluindo as imunodeficiências primárias. Eles podem e devem receber as vacinas em uso contra o SARS-CoV-2, mas nem sempre apresentarão uma resposta imunológica satisfatória e protetora, e, portanto, seus contactantes também devem ser vacinados.
Palavras-chave
Abstract
Since the beginning of the COVID-19 pandemic, the race for an active, effective, and safe immunization has started. All vaccines developed to date have shown good efficacy in preventing serious cases of COVID-19, hospitalization, and death. Many patients with inborn errors of immunity will not be able to develop an immune response similar to that of immunocompetent individuals. These patients were included in the priority groups defined by the Brazilian Ministry of Health, as people between 18 and 59 years of age with one or more comorbidities, including primary immunodeficiencies. They can and should receive the vaccines in use against SARS-CoV-2, but they will not always have a satisfactory and protective immune response, and, therefore, those in direct contact with them should also be vaccinated.
Keywords
Referências
1. Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. COVID‑19: Coronavirus Vaccine Development Updates. Front Immunol. 2020;11:602256.
2. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114.
3. Prüß BM. Current State of the First COVID-19 Vaccines. Vaccines (Basel). 2021;9(1):E30.
4. Glover RE, Urquhart R, Lukawska J, Blumenthal KG. Vaccinating against covid-19 in people who report allergies BMJ. 2021;372:n120
5. UKPIN. COVID-19 vaccines and PID [site na internet]. Disponível em: http://www.piduk.org/whatarepids/management/covid19vaccinesandpid
6. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).
7. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515).
8. British Society for Immunology. British Society for Immunology statement on COVID-19 vaccines for patients who are immunocompromised or immunosuppressed [site na internet]. Disponível em: https://www.immunology.org/news/bsistatement-covid-19-vaccines-for-patients-immunocompromisedimmunosuppressed.
9. European Society for immunodeficiencies. ESID COVID-19 Statement [site na internet]. Disponível em: https://esid.org/COVID19/ESID-COVID-19-Statement.
10. Sociedade Brasileira de Imunizações e Associação Brasileira de Alergia e Imunologia. Guia de Imunização SBIm/ASBAI 2020/2021 – Asma, Alergia e Imunodeficiências. Disponível em: https://sbim.org.br/images/guias/guia-sbim-asbai-miolo-201013b-web.pdf.
Submetido em:
26/02/2021
Aceito em:
08/03/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email